



Complications post CAR-T Cell Therapy in Paediatric and Adult Patients

How to improve efficacy-future challenges

Malaga, Spain
16-18 January 2025

Welcome!

CAR-T therapies have established themselves as the standard of care in relapsed and refractory haematologic malignancies for a variety of indications. With an increasing number of patients and approved CAR-Ts, there is a growing body of evidence on the spectrum of complications, which are distinct from complications of hematopoietic cell transplantation.

This educational course will cover both common and rare complications and ongoing changes in the practices of monitoring, prophylaxis and treatment of these complications.

The joint effort of PDWP & TCWP will cover aspects both in paediatric and adult practice.

Special dedication of the meeting will be to aspects of nursing care in CAR-T recipients.

We welcome you to Málaga, fasten your seat belts and get prepared for CAR(T) crashes!

With best wishes,

Zinaida Perić — *Transplant Complications Working Party Chair*

Ivan Moiseev — *Transplant Complications Working Party Secretary*

Sophie Van Lancker — *Transplant Complications Working Party Nurse*

Krzysztof Kalwak — *Paediatric Diseases Working Party Chair*

Katharina Kleinschmidt — *Paediatric Diseases Working Party Secretary*

Ida Bremer-Ophorst — *Paediatric Diseases Working Party Nurse*

Alberto Mussetti — *Local Organizer*



Complications post CAR-T Cell Therapy in Paediatric and Adult Patients

How to improve efficacy-future challenges

Malaga, Spain
16-18 January 2025

Thursday, 16 January 2025 Nurses' Track | Aduana Room

15:00 – 16:45 **Session NG I: CAR-T: What, Why & When**
Chairs: *Sophie van Lancker (BE) & Ida Bremer Ophorst (NL)*

This session will give a general overview of CAR-T treatment in adult and paediatric care. What is CAR-T, what is the indication, what licensed products are used, which differences are there in sequence of CAR-T treatment.

15:00 – 15:15	Welcome from the organizers	Sophie van Lancker (BE) Ida Bremer Ophorst (NL)
15:15 – 15:35	CAR-T in adult and paediatric care	Ruth Clout (UK)
15:35 – 15:55	Apheresis: cell collection for CAR-T treatment in adult and paediatric patient	Natalia Lorente del Rio (ES)
15:55 – 16:10	Paediatric case presentation on nursing perspectives about neurotoxicity's and CRS	Irene Trueba (ES)
16:10 – 16:25	Adult case presentation on nursing perspectives about neurotoxicity's and CRS	Ruth Clout (UK)
16:25 – 16:45	ICU perspective	Zoë Acke (BE)

16:45 – 17:15 **Coffee Break**

17:15 – 18:45 **Session NG II: CAR-T, the real Life experience**
Chairs: *Marjola Gjergji (IT) & Daphna Hutt (IL)*

This session will give a more in depth view of what kind of information do we give, how do nurses give and manage information, what tools do they use, what difference are there between adult and paediatric information and communication. What is patients or parents overall experience with CAR-T care.

17:15 – 17:35	The Role of bridging therapy in CAR-T setting	Daphna Hutt (IL)
17:35 – 17:55	Information and communication	Sophie van Lancker (BE) Ida Bremer Ophorst (NL)
17:55 – 18:15	Psycho-social care: The need of the patient and family?	Chiara Roebben (BE)
18:15 – 18:30	Patient and parent experience	Patricia Cáceres (ES)
18:30 – 18:45	Q&A	

Friday, 17 January 2025 Physicians' track | Caleta Room

09:00 – 09:10 **Welcome from the organizers**
Chairs: *Krzysztof Kalwak (PL), Alberto Mussetti (ES) & Zinaida Perić (HR)*

09:10 – 10:55 **Session I: Patient journey through CAR-T therapies: panel discussion**
Chairs: *Katharina Kleinschmidt (DE) & Zinaida Perić (HR)*
Panellists: *Olaf Penack (DE), Leyre Bento (ES), Giovanna Lucchini (IT)*

Case presentation by Andrea Palasciano (UK): Patient journey through CAR-T therapies, Cytokine release syndrome after CAR-T therapies, Infectious complications after CAR-T therapy

The session will cover the risk factors for failed CAR-T production, bridging therapies, risk factors for immune complications, risk factors for non-immune complications, aspects of doctor-patient interaction when consulting a patient, options for choosing a particular product in different countries, and aspects of follow-up.

10:55 – 11:25 **Coffee Break**

For further information, please contact education.events@ebmt.org

11:25 – 13:10 Session II: Supportive care and monitoring

Chairs: *Krzysztof Kałwak (PL) & Giovanna Lucchini (IT)*

11:25 – 12:25 Prophylaxis of cytokine release syndrome: pro and contra

Panellists: *Krzysztof Kałwak (PL), Jacopo Mariotti (IT) & Giovanna Lucchini (IT)*

This part of the session will cover the existing body of evidence on using prophylaxis in CAR-T recipients and the selection of patients for such prophylaxis. The spectrum of potential target therapies for prophylaxis will be covered.

12:25 – 13:10 Supportive care and monitoring: panel discussion

Panellists: *Michelle Kenyon (UK), Grzegorz Basak (PL), Victor Noriega (ES)*

In this part of the session, the presenters will describe the existing recommendations on supporting care and evaluation of symptoms at various stages after CAR-T therapies. The necessary minimum of laboratory and instrumental workouts will be described.

13:10 – 14:10 Lunch Break

14:10 – 15:20 Session III: Cytokine release syndrome after CAR-T therapies

Chairs: *Alberto Mussetti (ES) & Giovanna Lucchini (IT)*

The session is intended to teach the spectrum of clinical manifestations of CRS, the necessary laboratory and instrumental confirmatory studies, potential histological findings, and differences in presentation in the paediatric and adult populations. The treatment part will cover the optimal timing for initiation of therapy, first and subsequent lines of therapy, and evaluation of response.

14:10 – 14:40	A spectrum of clinical presentations and treatment in paediatric patients	Krzysztof Kałwak (PL)
14:40 – 15:00	A spectrum of clinical presentations and treatment in adult and elderly patients	Olaf Penack (DE)
15:00 – 15:10	<i>Case Presentation: Dexamethasone prophylaxis to reduce CRS or ICANS after axicel infusion: real life experience at a single centre</i>	M. Isabel Sotelo (ES)
15:10 – 15:20	<i>Case Presentation: Axicabtagene-ciloleucl for diffuse large B Cell lymphoma in an octogenarian patient: long-term remission and successful management of toxicities</i>	Eurides Rosa (BR)

15:20 – 15:50 Coffee Break

15:50 – 17:20 Session IV: Neurologic complications of CAR-T therapies

Chairs: *Jochen Büchner (NO) & Roser Velasco (ES)*

The session focuses on tools to monitor for ICANS and other manifestations of neurotoxicity, and the utility of imaging methods. Treatment overview will include corticosteroids, anti-cytokine, and anticonvulsant therapies. After the session, the attendees will be able to implement monitoring and early intervention protocols in their hospitals.

15:50 – 16:20	Managing patients with central nervous system involvement	Teresa Calimeri (IT)
16:20 – 16:40	Emerging strategies for managing ICANS	Christian Schultze-Florey (DE)
16:40 – 17:00	Non-ICANS neurological complications	Roser Velasco (ES)
17:00 – 17:20	Fludarabine-related neurotoxicity: truth or myth?	Roser Velasco (ES)



Complications post CAR-T Cell Therapy in Paediatric and Adult Patients

How to improve efficacy-future challenges

Malaga, Spain
16-18 January 2025

Friday, 17 January 2025
Nurses' track | Aduana room

09:30 – 11:00 **Session NG III: The changing face of CAR T therapy and developments (part I)**

Chairs: *Sophie van Lancker (BE) & Maria Finch (UK)*

This session intends to reflect on the care of CAR-T which is changing. Presenters will zoom in on developments and new technologies. What does this mean for the patient and for the or the care givers?

09:30 – 09:50	Ambulatory care (adult care)	Nuria Ballestar (ES)
09:50 – 10:10	The place of AI in CAR-T	Alberto Mussetti (ES)
10:10 – 10:40	Round table: ethical issues, self-care, boundaries in healthcare, and advanced care planning	
10:40 – 11:00	Summary moment of all round table groups	

11:00 – 11:25 **Coffee Break**

14:10 – 15:30 **Session NG IV: The changing face of CAR T therapy and developments (part II)**

Chairs: *Ida Bremer Ophorst (NL) & Julia Ruiz Pato (ES)*

This session intends to reflect on the care of CAR-T which is changing. In this session the presenters will zoom in on developments and new technologies and gives a change to work together to solve CAR-T problems.

14:10 - 14:30	The next step: CAR-T in solid tumours	Marjola Gjergji (IT)
14:30 - 14:45	<i>Case Presentation:</i> "How does everyone stay on board?" The process of continuous CAR-T education of the entire Pediatric Hemato-oncology team	Liesbeth Steendam (BE)
14:45 - 15:00	<i>Case Presentation:</i> A late complication of pneumocystis pneumonia following CAR-T Cell Therapy	Polly Pattenden (UK)
15:00 - 15:30	Escape Box: Get interactive in CAR-T care	
15:30 - 16:00	Summary and farewell	

Saturday, 18 January 2025
Physicians' track | Caleta Room

09:00 – 10:00 **Session V: Infectious complications after CAR-T therapy**

Chairs: *Rafael de la Cámara (ES) & Ivan Moiseev (RU)*

This session will provide an overview of recommendations on prophylaxis, current clinical practice, and recommendations on empirical antibacterial and antifungal therapies. The session will also cover difficulties of identifying patients with infections after anti-cytokine therapies, and practical recommendations on antimicrobial therapy in difficult diagnostic situations.

09:00 – 09:20	Current recommendations on prophylaxis of infections after CAR-T therapies	Ivan Moiseev (RU)
09:20 – 09:40	Differential diagnosis of sepsis and CRS, principles of empirical antimicrobial therapy after CAR-T therapies	Martina Pennisi (IT)
09:40 – 10:00	<i>Case Presentation:</i> Sporadic Toxicities of CAR T-Cell Therapy: A brief write-up	Bala Bhasker (QA)

10:00 – 10:30 **Coffee Break**

For further information, please contact education.events@ebmt.org



Complications post CAR-T Cell Therapy in Paediatric and Adult Patients

How to improve efficacy-future challenges

Malaga, Spain
16-18 January 2025

10:30 – 12:25 **Session VI: Rare CAR-T complications**

Chairs: *Ivan Moiseev (RU) & Charlotte Graham (UK)*

The session will discuss rare cases of complications after CAR-T therapies, like HLH/MAS, late cytopenia, graft-versus-host disease, pseudo progression and TA-TMA, as well as approaches to their treatment.

10:30 – 10:50 Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) after CAR-T: differential diagnosis from “common” CRS

10:50 – 11:10 Cytopenia after CAR-T: clinical presentation and treatment

11:10 – 11:30 Coagulopathy and endothelitis post CART

11:30 – 11:50 Late complications after CAR-T therapies

11:50 – 12:25 “Never give up until you really have to” case presentation and discussion

Giovanna Lucchini (IT)

Veit Buecklein (DE)

Silvana Novelli (ES)

Charlotte Graham (UK)

Jowita Frączkiewicz (PL)

12:25 – 12:30 **Summary and Farewell**



Complications post CAR-T Cell Therapy in Paediatric and Adult Patients

How to improve efficacy-future challenges

Malaga, Spain
16-18 January 2025

SPECIAL THANKS TO OUR SPONSORS

SILVER PARTNERS

Johnson & Johnson



Miltenyi Biotec